Stocks · News reference
Adicet Bio Q2 EPS $(1.99) Beats $(2.03) Estimate
Adicet Bio (NASDAQ:ACET) reported quarterly losses of $(1.99) per share which beat the analyst consensus estimate of $(2.03) by 1.97 percent. This is a 63.42 percent increase over losses of $(5.44) per share from the
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
8-K filing — Adicet Bio, Inc. (ACET)
Filed: 2026-09-01 AccNo: 0001720580-26-000054 Size: 208 KB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Adicet Bio Reveals FDA Clearance Of IND Application For ADI-212; Co Plans To Initiate Phase 1 Enrollment In Patients With mCRPC In Q4 Of 2026
Adicet Bio, Inc. (NASDAQ:ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta CAR T cell and in vivo CAR T therapies for autoimmune diseases, hematologic malignancies and solid
Guggenheim Maintains Buy on Adicet Bio, Lowers Price Target to $90
Guggenheim analyst Yatin Suneja maintains Adicet Bio (NASDAQ:ACET) with a Buy and lowers the price target from $100 to $90.